What is Bristol-Myers Squibb's short-term debt and current portion of long-term debt?

Bristol-Myers Squibb (BMY) reported short-term debt and current portion of long-term debt of $2.31B in Q1 2026.

How has Bristol-Myers Squibb's short-term debt and current portion of long-term debt changed year-over-year?

Bristol-Myers Squibb's short-term debt and current portion of long-term debt decreased by 35.1% year-over-year, from $3.55B to $2.31B.

What is the long-term trend for Bristol-Myers Squibb's short-term debt and current portion of long-term debt?

Over 5 years (2020 to 2025), Bristol-Myers Squibb's short-term debt and current portion of long-term debt has grown at a -0.7% compound annual growth rate (CAGR), from $2.34B to $2.26B.

Other

Short-term debt and current portion of long-term debt

Bristol-Myers Squibb Short-term debt and current portion of long-term debt increased by 2.1% to $2.31B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 35.1%, from $3.55B to $2.31B. Over 5 years (FY 2020 to FY 2025), Short-term debt and current portion of long-term debt shows relatively stable performance with a -0.7% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.

Analysis

StatementBalance Sheet Statement

SectionOther

CategoryLiquidity

SignalLower is better

VolatilityModerate

First reportedQ4 2014

Last reportedQ1 2026Apr 30, 2026

How to read this metric

Lower levels reduce immediate liquidity pressure, while high levels may signal a need for refinancing or significant cash outflows.

Detailed definition

The portion of total debt obligations, including bank loans and notes, that is due for repayment within the next twelve...

Peer comparison

A key indicator of short-term financial health compared to peers with similar capital structures.

Metric ID: other_debt_current

Historical Data

20 periods

	Q2 '21	Q3 '21	Q4 '21	Q1 '22	Q2 '22	Q3 '22	Q4 '22	Q1 '23	Q2 '23	Q3 '23	Q4 '23	Q1 '24	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Value	$2.66B	$5.07B	$4.95B	$7.52B	$4.95B	$2.13B	$4.26B	$2.75B	$3.02B	$5.47B	$3.12B	$6.19B	$3.53B	$1.08B	$2.05B	$3.55B	$4.72B	$4.51B	$2.26B	$2.31B
QoQ Change	—	+90.8%	-2.3%	+52.0%	-34.2%	-57.0%	+100.0%	-35.5%	+9.7%	+81.0%	-42.9%	+98.5%	-43.0%	-69.5%	+89.8%	+73.7%	+32.7%	-4.4%	-49.9%	+2.1%
YoY Change	—	—	—	—	+86.6%	-57.9%	-13.8%	-63.4%	-39.0%	+156.4%	-26.9%	+124.9%	+16.9%	-80.3%	-34.4%	-42.6%	+33.5%	+318.3%	+10.5%	-35.1%

Range$1.08B – $7.52B

CAGR-2.9%

Avg YoY Growth+22.1%

Median YoY Growth-20.3%

Short-term debt and current portion of long-term debt at Other Companies

PfizerPFE View metric

Merck & Co.MRK View metric

Gilead SciencesGILD View metric

ViatrisVTRS View metric

Eli LillyLLY View metric

Frequently Asked Questions

What is Bristol-Myers Squibb's short-term debt and current portion of long-term debt?: Bristol-Myers Squibb (BMY) reported short-term debt and current portion of long-term debt of $2.31B in Q1 2026.
How has Bristol-Myers Squibb's short-term debt and current portion of long-term debt changed year-over-year?: Bristol-Myers Squibb's short-term debt and current portion of long-term debt decreased by 35.1% year-over-year, from $3.55B to $2.31B.
What is the long-term trend for Bristol-Myers Squibb's short-term debt and current portion of long-term debt?: Over 5 years (2020 to 2025), Bristol-Myers Squibb's short-term debt and current portion of long-term debt has grown at a -0.7% compound annual growth rate (CAGR), from $2.34B to $2.26B.
What does short-term debt and current portion of long-term debt mean?: The amount of debt that must be paid back within one year.